Journal: Oncology Reports

Article Title: Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer

doi: 10.3892/or.2023.8610

Figure Lengend Snippet: FOXF1 expression is downregulated in tumor tissues and is associated with a poor prognosis of patients with BC. (A) Expression of FOXF1 in pan-cancer and (B) BC tissues in the Ruijin Cohort. The association of the FOXF1 expression levels with (C) tumor type, (D) pathological grade, (E) muscle invasion, (F) T stage and (G) American Joint Committee on Cancer stage in the Ruijin Cohort. (H) The H-score curve and (I) survival status of FOXF1-low group and FOXF1-high group in the Ruijin Cohort; patients were listed in an order of increased FOXF1 expression level; the dotted line represents the cut-off value between the two groups. (J) Kaplan-Meier analysis of overall survival in the Ruijin Cohort and (K) in the GSE48075 dataset. FOXF1, forkhead box F1; BC, bladder cancer; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma.

Article Snippet: Subsequently, the microarray was incubated with primary antibody against human FOXF1 (1:100 dilution; cat. no. PAB30083, Abnova) overnight at 4°C.

Techniques: Expressing

Journal: Oncology Reports

Article Title: Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer

doi: 10.3892/or.2023.8610

Figure Lengend Snippet: Association between FOXF1 expression and the clinicopathological characteristics of patients with BC.

Article Snippet: Subsequently, the microarray was incubated with primary antibody against human FOXF1 (1:100 dilution; cat. no. PAB30083, Abnova) overnight at 4°C.

Techniques: Expressing

Journal: Oncology Reports

Article Title: Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer

doi: 10.3892/or.2023.8610

Figure Lengend Snippet: dsFOXF1-367 induces FOXF1 expression in human BC cells. The mRNA expression level of FOXF1 was downregulated in (A) bladder tumor tissues and (B) BC cells lines. (C) The protein expression levels of FOXF1 in T24 and EJ cells were assessed using western blot analysis; GAPDH served as the loading control; (D) the relative FOXF1 protein expression levels were quantified by determining the gray value. (E) Subcellular expression of FOXF1 protein (red) in T24 and (F) EJ cells was detected using immunofluorescence (magnification, ×400); nuclei were stained with DAPI (blue). *P<0.05, **P<0.01 and ***P<0.001, vs. respective control. FOXF1, forkhead box F1; BC, bladder cancer.

Article Snippet: Subsequently, the microarray was incubated with primary antibody against human FOXF1 (1:100 dilution; cat. no. PAB30083, Abnova) overnight at 4°C.

Techniques: Expressing, Western Blot, Control, Immunofluorescence, Staining

Journal: Oncology Reports

Article Title: Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer

doi: 10.3892/or.2023.8610

Figure Lengend Snippet: dsFOXF1-367 suppresses cell proliferation, migration, invasion and induces apoptosis in BC. CCK-8 assays were used to examine the viability of (A) T24 and (B) EJ cells. EdU assays revealed that dsFOXF1-367 inhibited (C) T24 and (D) EJ cell proliferation. The replicating DNA were marked with Apollo567 (orange), while nuclei were stained with DAPI (blue; magnification, ×200). (E) Proportion of replication DNA in T24 and EJ cells. (F) dsFOXF1-367 impaired the clonogenic capacity of T24 and EJ cells; (G) the colony formation rate in each group was compared in the histogram. (H and I) Representative images (magnification, ×200) of Transwell assays (H) with or (I) without Matrigel in T24 and EJ cells; the numbers of (J) migrated and (K) invaded cells were compared. Flow cytometry of (L and M) T24 cells following transfection with (L) dsControl or (M) dsFOXF1-367, and (N and O) EJ cells following transfection with (N) dsControl or (O) dsFOXF1-367. Percentages of (P) T24 and (Q) EJ cells in early and late apoptosis. (R) The heatmap revealed 1,178 protein coding genes among 34,715 genes which were possibly regulated by FOXF1 activation. (S) Protein-protein interaction network of potential hub genes and (T) the interaction degree of top 10 genes. (U) The protein expression levels of apoptosis-related genes. *P<0.05, **P<0.01 and ***P<0.001, vs. dsControl. FOXF1, forkhead box F1; BC, bladder cancer.

Article Snippet: Subsequently, the microarray was incubated with primary antibody against human FOXF1 (1:100 dilution; cat. no. PAB30083, Abnova) overnight at 4°C.

Techniques: Migration, CCK-8 Assay, Staining, Flow Cytometry, Transfection, Activation Assay, Expressing

Journal: Oncology Reports

Article Title: Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer

doi: 10.3892/or.2023.8610

Figure Lengend Snippet: Promoting effect of FOXF1 on the apoptosis of T24 and EJ cells is reversed by caspase-3 inhibitor. Apoptosis assays of T24 cells treated with (A) dsControl, (B) dsControl plus caspase inhibitor, (C) dsFOXF1-367 and (D) dsFOXF1-367 plus caspase inhibitor, respectively. (E) Percentage of T24 cells undergoing apoptosis and (F) cell viability in each group. The apoptosis assays of EJ cells treated with (G) dsControl, (H) dsControl plus caspase inhibitor, (I) dsFOXF1-367 and (J) dsFOXF1-367 plus caspase inhibitor, respectively. (K) Percentage of EJ cells undergoing apoptosis and (L) cell viability in each group. **P<0.01 and ***P<0.001, vs. dsControl or as indicated. The cell apoptotic rates in the dsFOXF1-367(+) Ac-DEVD-CHO(−) groups were compared with those in the dsControl(+) Ac-DEVD-CHO(−) groups, and the cell apoptotic rates in the dsFOXF1-367(+) Ac-DEVD-CHO(+) groups were compared with those in the dsFOXF1-367(+) Ac-DEVD-CHO(−) groups, respectively. FOXF1, forkhead box F1.

Article Snippet: Subsequently, the microarray was incubated with primary antibody against human FOXF1 (1:100 dilution; cat. no. PAB30083, Abnova) overnight at 4°C.

Techniques:

Journal: Oncology Reports

Article Title: Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer

doi: 10.3892/or.2023.8610

Figure Lengend Snippet: Activation of FOXF1 suppresses the tumorigenesis of EJ cells in vivo . (A) The procedure of injection, weighting and measuring of xenograft tumor models. (B) EJ Lenti-dsControl and EJ Lenti-dsFOXF1-367 cells (6×10 6 , 200 µl) were injected into the right flanks of the mice; the mice were examined for 30 days. (C) Subcutaneous tumors in each group were dissected and photographed. (D and E) Body weights and tumor volumes in each group. *P<0.05 and **P<0.01. The image in (A) was created using BioRender.com. FOXF1, forkhead box F1.

Article Snippet: Subsequently, the microarray was incubated with primary antibody against human FOXF1 (1:100 dilution; cat. no. PAB30083, Abnova) overnight at 4°C.

Techniques: Activation Assay, In Vivo, Injection

Journal: Oncology Reports

Article Title: Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer

doi: 10.3892/or.2023.8610

Figure Lengend Snippet: The mechanisms of the antitumor signaling of dsFOXF1-367 in bladder tumors. The figure was created using BioRender.com. FOXF1, forkhead box F1; Ago 2, Argonaute 2.

Article Snippet: Subsequently, the microarray was incubated with primary antibody against human FOXF1 (1:100 dilution; cat. no. PAB30083, Abnova) overnight at 4°C.

Techniques:

Journal: Oncotarget

Article Title: A novel microfluidic model can mimic organ-specific metastasis of circulating tumor cells

doi: 10.18632/oncotarget.9382

Figure Lengend Snippet: ( A – C ) Typical metastatic colonies of MCF-7, MDA-MB-231, and ACC-M cells after HE staining and anti-human Pan CK immunostaining in the lung of nude mice. The metastatic colonies are circumscribed by black dotted lines and indicated by asterisk. Scale bar = 50 μm. ( D ) The metastasis rates and the colony numbers of MCF7, MDA-MB-231, and ACC-M, respectively. ( E ) The metastasic colony areas of MCF-7, MDA-MB-231, and ACC-M cells. The colony areas of MDA-MB-231 cells were significantly higher than those of MCF-7 cells (** p < 0.01, n = 5 per group).

Article Snippet: Immunohistochamical staining with anti-humna Pan CK (Merckmillipore, USA) was performed to detect the metastatic colonies.

Techniques: Staining, Immunostaining

Journal: PLoS ONE

Article Title: Impairment of Type I but Not Type III IFN Signaling by Hepatitis C Virus Infection Influences Antiviral Responses in Primary Human Hepatocytes

doi: 10.1371/journal.pone.0121734

Figure Lengend Snippet: Transcriptional profiling of PHH infected with HCVcc at an MOI of 0.2. (A) Relative expression of genes involved in the PAMP recognition pathway showing data from three replicates at 24 h or 48 h post-infection normalized to naive PHH at the same time points. HUGO nomenclature for the genes is to the left. Statistical analysis was performed using one-way ANOVA and P values reported in (B) Expression levels of IFNAR1 and IL28RA transcripts in naive (closed circle) and HCVcc-infected (open circle) PHH. The data points represent the RMA values from each individual analyte and horizontal bars indicate the mean levels from three biological replicates. The data shown is representative of two independent experiments.

Article Snippet: Briefly, iHLCs were infected with HCVcc at multiplicity of infection (MOI) of 0.2 and incubated for 4–6 days in presence or absence of a neutralizing monoclonal antibody directed against the extracellular domain of the IL28RA receptor subunit (ZymoGenetics).

Techniques: Infection, Expressing

Journal: PLoS ONE

Article Title: Impairment of Type I but Not Type III IFN Signaling by Hepatitis C Virus Infection Influences Antiviral Responses in Primary Human Hepatocytes

doi: 10.1371/journal.pone.0121734

Figure Lengend Snippet: iHLCs were infected with HCVcc (MOI of 0.2), GT-1b HCVser or mock infected, and subsequently maintained in culture with medium replacement every 2 days. At 24 h post-infection, the NS3 PI ASV (0.5 μM) or vehicle control dimethyl sulfoxide (DMSO) was added to cell cultures during media replenishment. (A) Persistent HCVcc replication as measured by the detection of the virally-encoded core antigen and expression of type I (IFNAR1, IFNAR2) and type III IFN (IL28RA, IL10RB) co-receptor subunits in cells were monitored by Western immunoblotting at the indicated time points, with β-actin used as loading control. Right panel; Relative intensity of IFNAR1 detected in HCVcc infected cells maintained in the presence (open triangle) or absence (open square) of ASV treatment was quantified by densitometry analysis, normalized to β-actin levels in each sample, and expressed as a percentage relative to mock-infected cells. Data are representative of three independent Western immunoblot analyses. (B) Co-localization of IFNAR1 and HCV-core positive iHLCs were assessed by fluorescence microscopy. On Day 6 post-infection, naive and HCVcc-infected iHLCs were fixed, permeabilized and stained with antibodies to IFNAR1 (red) and HCV core antigen (green) as indicated. Nuclei were counterstained with Hoechst dye (blue) as shown in the overlays. (C) iHLC cultures infected in parallel with GT-1b HCVser or HCVcc were harvested at the indicated time points and IFNAR1 copy numbers estimated by quantitative RT-PCR following normalization to cellular GAPDH levels in each sample. Results are expressed as mean ± standard deviations (n = 4). Statistical analysis was performed by Bonferroni’s multiple comparison tests: **, P < 0.05; ***, P < 0.001. (D) Cell lysates were harvested at the indicated time points and protein levels of IFNAR1 and IL28RA were examined by Western immunoblotting. Susceptibility of HCVser to the NS3 PI ASV was determined using an antibody directed against NS3. Arrows indicate the presence of the processed and unprocessed forms of the HCV-encoded NS3/4A protease in infected iHLCs. Detection of β-actin served as loading control. Right panel; Relative intensity of IFNAR1 detected in HCVser infected cells maintained in the presence (open triangle) or absence (open square) of ASV treatment was quantified by densitometry analysis, normalized to β-actin levels in each sample, and expressed as a percentage relative to mock-infected cells. Data are representative of two independent Western immunoblot analyses.

Article Snippet: Briefly, iHLCs were infected with HCVcc at multiplicity of infection (MOI) of 0.2 and incubated for 4–6 days in presence or absence of a neutralizing monoclonal antibody directed against the extracellular domain of the IL28RA receptor subunit (ZymoGenetics).

Techniques: Infection, Control, Expressing, Western Blot, Fluorescence, Microscopy, Staining, Quantitative RT-PCR, Comparison

Journal: PLoS ONE

Article Title: Impairment of Type I but Not Type III IFN Signaling by Hepatitis C Virus Infection Influences Antiviral Responses in Primary Human Hepatocytes

doi: 10.1371/journal.pone.0121734

Figure Lengend Snippet: (A) Naive and HCVcc infected iHLC cultures maintained in presence or absence of the IL28RA nAb were treated for 15 minutes with 10 ng/mL or 100 ng/mL of alfa or Lambda. Cell lysates were then prepared, and equal amounts of proteins subjected to Western immunoblotting to examine the levels of STAT1 phosphorylation using an antibody directed against phospho STAT1 (pSTAT1; Tyr701). Detection of total STAT1 served as loading control to ensure that equivalent amounts of protein were analyzed among samples. (B) Phosphorylation of STAT1 in iHLCs was evaluated upon stimulation using the Luminex bead-based assay. MFI values were reported as mean values of three independent cultures. Error bars show the standard deviations. Two-way ANOVA statistical analysis was performed using Bonferroni post test: ***, P < 0.001.

Article Snippet: Briefly, iHLCs were infected with HCVcc at multiplicity of infection (MOI) of 0.2 and incubated for 4–6 days in presence or absence of a neutralizing monoclonal antibody directed against the extracellular domain of the IL28RA receptor subunit (ZymoGenetics).

Techniques: Infection, Western Blot, Phospho-proteomics, Control, Luminex, Bead-based Assay

Journal: PLoS ONE

Article Title: Impairment of Type I but Not Type III IFN Signaling by Hepatitis C Virus Infection Influences Antiviral Responses in Primary Human Hepatocytes

doi: 10.1371/journal.pone.0121734

Figure Lengend Snippet: (A) Expression of Mx1 protein (red) and HCV-core antigen (green) was monitored in HCVcc-infected iHLC cultures maintained in presence or absence of the IL28RA nAb (10 μg/mL). Dual immunostaining was performed as described in the legend for . Nuclei were counterstained with Hoechst dye (blue) as shown in the overlays. (B) Induction of Mx1 expression (red) was assessed in Naive iHLCs 24 h following stimulation with 10 ng/mL of alfa (a) or Lambda (b). iHLC cultures infected with HCVcc were maintained in the presence (left panels) or absence (right panels) of the IL28RA nAb (10 μg/mL). On Day 6 post-infection, cells were treated as indicated with 10 ng/mL of alfa or Lambda for 24 h, and then dual immunostaining was performed using antibodies directed against Mx1 (red) and the HCV-core antigen (green). Arrows indicate examples of different HCV-Mx1 co-localization patterns in overlaid optical field. Scale bar, 60 μm.

Article Snippet: Briefly, iHLCs were infected with HCVcc at multiplicity of infection (MOI) of 0.2 and incubated for 4–6 days in presence or absence of a neutralizing monoclonal antibody directed against the extracellular domain of the IL28RA receptor subunit (ZymoGenetics).

Techniques: Expressing, Infection, Immunostaining

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Immunohistochemical expression of galanin receptors (GALR1, GALR2, and GALR3) in myenteric plexuses (MP) distantly located from the colorectal cancer (CRC) tissue compared with their expression in the myenteric plexuses in the vicinity of cancer invasion of the same, representative CRC patients (n = 31). Neurons expressing respective GALRs are marked by arrows. Total magnification: 400× g .

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques: Immunohistochemical staining, Expressing

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Immunoreactivity (IR) of galanin receptors (GALR1—( A ), GALR2—( C ), and GALR3—( E )) in myenteric plexuses (MP) distantly and proximity located to cancer invasion in individual colorectal (CRC) patients. The average immunoreactivities of GALRs (GALR1—( B ), GALR2—( D ), and GALR3—( F )) in myenteric plexuses (MP) located distantly from CRCcells were compared with those in plexuses in the vicinity of cancer cells of colorectal (CRC) patients (n = 31).

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques:

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Immunolocalization of galanin receptors (GALR1, GALR2, and GALR3) in myenteric plexuses (MP) close and distant to tumour tissue of CRCpatients (n = 5). Neurons expressing respective GALRs are marked by arrows. Total magnification: 400× g .

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques: Expressing

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Kaplan–Meier diagrams that show the relative immunoexpression of galanin receptors (GALR1—( A ), GALR2—( B ), and GALR3—( C )) in myenteric plexuses (MP) regarding the overall survival of colorectal cancer (CRC) patients (n = 31).

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques:

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Analysis of overall survival of CRC patients in relation to GALRs immunoexpression in myenteric plexuses. HR-hazard ratio; CI-confidence interval; MP-myenteric plexus.

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques:

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Associations between demographic and clinico-pathological features of colorectal cancer patients (n = 31) and relative expression levels of galanin receptors in myenteric plexuses determined by immunohistochemistry.

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques: Expressing, Immunohistochemistry

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Immunohistochemical expression of galanin receptors (GALR1, GALR2, and GALR3) in submucosal plexuses (SP) distantly located from the colorectal cancer (CRC) tissue compared with their expression in the submucosal plexuses in the vicinity of cancer invasion of the same, representative CRC patients (n = 32). Neurons expressing respective GALRs are marked by arrows. Total magnification: 400× g .

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques: Immunohistochemical staining, Expressing

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Immunoreactivity (IR) of galanin receptors (GALR1—( A ), GALR2—( C ), and GALR3—( E )) in submucosal plexuses (SP) distantly and in proximally located to cancer invasion in individual colorectal (CRC) patients. The average immunoreactivities of GALRs (GALR1—( B ), GALR2—( D ), and GALR3—( F )) in submucosal plexuses (SP) located distantly from CRC tissue were compared with those in plexuses in the vicinity of cancer cells of colorectal (CRC) patients (n = 31).

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques:

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Immunolocalization of galanin receptors (GALR1, GALR2, and GALR3) in submucosal plexuses (SP) close and distant to tumour tissue of colorectal cancer patients (n = 5). Neurons expressing respective GALRs are marked by arrows. Total magnification: 400× g .

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques: Expressing

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Kaplan–Meier diagrams that show the relative immunoexpression of galanin receptors (GALR1—( A ), GALR2—( B ), and GALR3—( C )) in submucosal plexuses (SP) regarding the overall survival of colorectal cancer (CRC) patients (n = 32).

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques:

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Analysis of overall survival of CRC patients in relation to GALRs immunoexpression in submucosal plexuses. HR-hazard ratio; CI-confidence interval; SP-submucosal plexus.

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques:

Journal: Biomolecules

Article Title: Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters

doi: 10.3390/biom12121769

Figure Lengend Snippet: Association between demographic and clinico-pathological features of colorectal (CRC) patients (n = 32) and relative expression levels of galanin receptors in submucosal plexuses determined by immunohistochemistry.

Article Snippet: The sections were incubated overnight at 4 °C with rabbit polyclonal anti-human antibodies against GALR1 (Cat. No. GTX108207, GeneTex, Irvine, CA, USA), GALR2 (Cat. No. GTX100382, GeneTex, Irvine, CA, USA) and GALR3 (Cat. No. GTX10816, GeneTex, Irvine, CA, USA), all diluted 1:400 in PBS.

Techniques: Expressing, Immunohistochemistry